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Abstract
Background: Although interim analysis approaches in clinical trials are widely known, information
on current practice of planned monitoring is still scarce. Reports of studies rarely include details
on the strategies for both data monitoring and interim analysis. The aim of this project is to
investigate the forms of monitoring used in cancer clinical trials and in particular to gather
information on the role of interim analyses in the data monitoring process of a clinical trial. This
study focused on the prevalence of different types of interim analyses and data monitoring in cancer
clinical trials.
Methods: Source of investigation were the protocols of cancer clinical trials included in the Italian
registry of clinical trials from 2000 to 2005. Evaluation was restricted to protocols of randomised
studies with a time to event endpoint, such as overall survival (OS) or progression free survival
(PFS). A template data extraction form was developed and tested in a pilot phase. Selection of
relevant protocols and data extraction were performed independently by two evaluators, with
differences in the data assessment resolved by consensus with a third reviewer, referring back to
the original protocol. Information was obtained on a) general characteristics of the protocol b)
disease localization and patient setting; c) study design d) interim analyses; e) DSMC.
Results: The analysis of the collected protocols reveals that 70.7% of the protocols incorporate
statistical interim analysis plans, but only 56% have also a DSMC and be considered adequately
planned. The most concerning cases are related to lack of any form of monitoring (20.0% of the
protocols), and the planning of interim analysis, without DSMC (14.7%).
Conclusion: The results indicate that there is still insufficient attention paid to the implementation
of interim analysis.
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Introduction
Importance of interim analyses
The simplest approach for evaluating results of a clinical
trial is to plan just one statistical analysis at the end of the
study, using a fixed-sample size design: planning and con-
duction are easy, and the methods for estimation are well
established. This approach, which is convenient and effec-
tive when all observations are available in a short period
of time, is less appropriate when data become available
sequentially. This is the case in studies on chronic dis-
eases, like cancer, in which recruitment may last many
years, so that the first outcomes can be observed when the
accrual is still ongoing. In such situations there might be
ethical, practical and economic reasons for looking at the
data before the planned end of the study.
Data monitoring conducted during a continuing study
may focus on performance, data integrity, safety and treat-
ment effect. The assessment of study performance in terms
of quality of data, protocol adherence, recruitment rate, is
normally performed periodically in an informal way,
adopting modalities that can be grouped under the defini-
tion of "internal monitoring". In contrast, the tasks of
"external monitoring" are to evaluate data integrity, safety
and efficacy of treatments and to provide advice on con-
tinuing the study as originally planned, or suggesting
changes in its conduct, or even on stopping it. This advice
is mainly based on trial results, but should take into
account the context of information external to the trial
available at the moment of the analysis[1].
This process of "interim analysis" is usually conducted by
a data and safety monitoring committee (DSMC), usually
composed by an independent group of experts in the
involved fields (biostatistician, clinical researcher, epide-
miologist, clinician with expertise in the disease under
investigation) [1,2].
Formal interim analysis offers several advantages, since
this approach makes the process of acquiring and dissem-
inating results more efficient and a beneficial treatment
can be made available sooner. Ethical reasons play also a
role in the decision to stop a trial, since there is a respon-
sibility to minimize the number of subjects treated with
an unsafe, ineffective or clearly inferior treatment. On the
other hand, conducting an interim analysis may also have
drawbacks, since immature results on small numbers of
patients will provide imprecise or even biased point and
interval estimates of the treatment effect, increasing the
error in inferential process [3]: when a clinical trial is
closed because a treatment difference has been detected,
the estimate of the magnitude of that difference will over-
state the "true" value [4]. Finally, trials stopped early are
likely to be of small size, and as a consequence their
results may lack both statistical precision and credibility,
since medical community might remain sceptical, even in
case of highly significant results. Therefore, while infor-
mal reviews are necessary, the process of repeatedly evalu-
ating data must be done with caution, especially early in
the course of a trial when the number of both participants
and events related to safety and efficacy are relatively
small [5]. For these reasons some investigators strongly
recommend that the results of such trials should be
treated with scepticism [6].
From the statistical viewpoint, monitoring methods can
be classified according to whether the method is frequen-
tist or Bayesian [7] and comprehensive reviews of statisti-
cal aspects of monitoring can be found in Whitehead [8],
Jennison and Turnbull [9] and Piantadosi [10]. However,
regardless of the specific method used, a key issue is that
statistical rules are only a part of the question, as they tend
to oversimplify the information relevant to the decision
that must be taken. The decision to stop a trial before the
prespecified final analysis should not be guided only by
statistical considerations, but also by practical issues (tox-
icity, ease of administration, costs, etc.), as well as clinical
considerations. For this reason it is preferable to refer to
statistical methods as guidelines, rather than rules [11].
Despite these statistical and ethical implications of con-
ducting an interim analysis, information on explicit adop-
tion of planned monitoring is still scarce, basically driven
by the published reports of studies, which rarely include
details on the strategies for data monitoring and interim
analysis. It seemed therefore of interest to investigate the
forms of monitoring and interim analysis used in ran-
domised clinical trials in cancer in order to gather infor-
mation of the quality of research protocols activated in
Italy on cancer patients.
Methods
We assessed protocols available in the OsSC database [12]
[see additional file 1] relative to oncological studies sub-
mitted to Italian ECs from January 1st 2000 to May 2005
and evaluated and accepted by the coordinating centre by
the end of October, 2005. We restricted the evaluation to
protocols of randomised studies with a time to event end-
point, such as overall survival (OS) or progression free
survival (PFS). A template data extraction form was devel-
oped and tested in a pilot phase. Selection of relevant pro-
tocols and data extraction were performed independently
by two evaluators, with differences in the data assessment
resolved by consensus with a third reviewer, referring back
to the original protocol.
Information was obtained on a) general characteristics of
the protocol (identification number, experimental phase,
year of EC opinion release, type of sponsor, involved
countries, study objective; b) disease localization and
patient setting; c) study design (aim of the study, primaryTrials 2008, 9:46 http://www.trialsjournal.com/content/9/1/46
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endpoint, number of arms, expected number of events to
observe and of patients to randomise, planned number of
centres involved in the trial, duration of the study, as well
as of the accrual and follow-up periods); d) interim anal-
yses, if present (number, type, objective, timing); e)
DSMC, if planned (composition and tasks).
Results were reported using adequate descriptive statistics,
such as absolute and relative frequencies for categorical
variables and median (interquartile range) for continuous
variables, unless otherwise specified.
The association between the use of interim analyses and/
or DSMC and potential determinants, such as type of
sponsor, involved countries, year of submission, experi-
mental phase and total duration of the study was esti-
mated by a logistic regression model. Results are reported
as odds ratios (ORs) and their 95% confidence intervals
(95% CIs).
Analyses were performed using SAS (Statistical Analysis
System, SAS Institute Inc., Cary, NC, US, Version 8.20)
software.
Results
Seven hundreds ninety-six cancer protocols were identi-
fied and manually checked in order to locate the eligible
trials.
Figure 1 reports the flow diagram of the selection of rele-
vant protocols [see additional file 2]. From 796 oncologi-
cal studies found, only 150 (18.8%) were eligible and
evaluable for analysis, while the others were excluded for
the reasons described in the diagram.
Table 1 describes the characteristics of evaluated trials [see
additional file 3].: the majority of the protocols included
in this project are international (102, 68.0%), and con-
ducted on solid tumours (129, 86.0%). The more fre-
quently investigated diseases are lung (36, 24.0%) and
breast cancers (35, 23.3%). 107 out of 129 (83.0%) of the
protocols on solid tumours were conducted in the setting
of advanced disease (data not shown). The great majority
(138, 92.0%) of the studies were aimed at detecting a dif-
ference in efficacy between arms, and the primary end-
point was overall survival in 64 cases (42.7%). The
planned median number of patients to randomise and of
events to observe was 520 (25°–75° percentiles: 300–
820) and 384 (25°–75° percentiles: 218–616), respec-
tively. The expected proportion of events at the end of the
study, a good index of patient prognosis, calculated as the
ratio of these two latter variables, had a median value of
0.69 (25°–75° percentiles: 0.47–0.78). The median study
duration was 42.5 months (25°–75° percentiles: 29–60),
given by a median accrual period of 24 months (25°–75°
percentiles: 18–36) and a subsequent follow-up of 18
(25°–75° percentiles: 12–30). The median number of
experimental centres was 70 (25°–75° percentiles: 35–
120), but this information is reported only in 65 proto-
cols.
Table 2 shows the presence of interim analyses and/or of
a DSMC [see additional file 4]. 106 (70.7%) protocols
planned some form of monitoring, for example on safety,
protocol compliance or recruitment rate. When focusing
on formal efficacy analysis, this number decreases to 86
(66.2%), because in 20 cases the only checks concerned
matters such as safety, feasibility and recruitment rate. The
establishment of a DSMC was reported in 98 (65.3%)
cases: 84 (56.0%) with a planned interim analysis and 14
(14.7%) in which an interim analysis was not planned.
Overall neither form of monitoring took place in 30 out
of 150 protocols (20.0%). The median number of interim
analyses was 2, ranging from 1 to 9. Among the 86 proto-
cols with an efficacy analysis, 34 (39.5%) planned only 1
interim analysis, 32 (37.2%) 2 interim analysis, 10
(11.6%) 3 interim analysis; and 10 (11.6%) more than 3
analyses,
Table 3 shows the main characteristics of the interim effi-
cacy analyses [see additional file 5]. Of note, among the
86 protocols with an efficacy analysis, in 2 cases the end-
point was not reported, while in 6 (7.0%) it was related to
activity, and therefore different from that of the final anal-
ysis.
The timing of interim analyses for efficacy was planned
according to the proportion of observed events (for exam-
ple for 2 analyses, the first when 33% of the planned total
number of events had been observed and the second at
66%) in 54 (62.8%) protocols, according to the propor-
tion of patients (for example again for 2 analyses after the
enrolment of 33% and 66% of the planned total number
of patients) in 22 (25.6%) protocols and based on calen-
dar time (for example yearly after the first two years of
recruitment) in the remaining 10 (11.6%) cases.
The most frequent type of statistical approach for the anal-
ysis was the frequentist method, using the O'Brien and
Fleming boundaries: alone in 45 out of 86 (52.3%) stud-
ies or together with conditional power in 6 (7.0%). Con-
ditional power alone was used in 6 studies, while a
Bayesian approach was used in only one study. In 5 pro-
tocols the statistical monitoring method, and therefore
the stopping rules, was not specified.
Criteria for stopping were reported in 77 (89.5%) of the
protocols, mostly represented by the achievement of a sig-
nificant difference between arms (52, 60.5%). It is of noteTrials 2008, 9:46 http://www.trialsjournal.com/content/9/1/46
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that in 2 studies, no mention was made of either the sta-
tistical approach or the stopping rules to be adopted.
In 24 (24.5%) out of 98 protocols, the only commitment
of DSMC was safety. Efficacy was considered in 68 proto-
cols (69.4%). In one study it was the only task of DSMC,
while in the remaining 67 the DSMC was in charge of
monitoring both safety and efficacy. The composition and
frequency of DSMC meetings are reported only in 34
(34.7%) and 40 (40.8%) protocols, respectively. The
DSMC was stated to be independent in 80 (81.6%) of the
protocols. The committee usually consisted of 3 or 4
members, always including a statistician, In 8 cases spon-
sor representatives could participate as non voting-mem-
ber. The frequency of the meetings was generally twice a
year.
Table 4 shows the results of univariate and multivariate
logistic models, assessing the association among selected
characteristics of the study protocols and the presence of
both interim analysis and DSMC [see additional file 6]. In
both models, the only variable associated with the pres-
ence of an interim analysis was the international organi-
zation of the study, accounting for an odds ratio of 3.72
(95% CI 1.70–8.13) and of 4.75 (95% CI 1.38–16.4),
respectively. The most important factors associated with
the presence of DSMC are a commercial sponsor (OR
4.37, 95% CI 1.38–13.9) and international collaboration
(OR 10.9, 95% CI 3.06–38.6).
Discussion
This project was aimed at assessing the prevalence of
interim analyses and DSMC in randomised clinical trials
in cancer, using as source the database including all phase
II-III trials submitted to Italian ECs from January 2000 to
May 2005. The Italian registry of clinical trials gave an
unique opportunity to obtain this information and
allowed a critical appraisal of the statistical designs uti-
lized in current cancer clinical trials in Italy.
The reason for choosing a protocol registry rather than lit-
erature data, stems from the observation that in published
papers the quality of details relative to the description of
statistical methods is often scarce, and it is possible that,
despite the accuracy of such a search strategy, the informa-
tion regarding the approaches adopted for monitoring
clinical trials is not completely or accurately captured.
Moreover, even when reported, statistical analysis of can-
cer published trials usually concerns protocols designed
years before the study publication and, as a consequence,
data derived from even the most recent published litera-
ture may not be completely appropriate to represent the
currents trend of interim analysis and DSMC use. Finally,
since Italian registry includes several international proto-
cols, it may also be considered an important source of
information generalizable also to ongoing researches in
European countries.
The most important conclusion arising from this study is
that at present around 30% of the protocols do not incor-
porate any form of interim analysis plan, and only 56% of
protocols can be considered adequately planned for mon-
itoring the trial. Although this result suggests an increas-
ing use of monitoring tools with respect to the past, it is
still not completely satisfactory. Despite the availability of
several statistical methods for interim analysis, the almost
uniquely approach is the frequentist method while the
Bayesian approach is rarely considered, although in the
context of monitoring it would be more useful for its char-
acteristics of flexibility in incorporating external evidence.
Interim analysis plans are still described very infrequently,
even in the more recent protocols, denoting insufficient
attention to this issue not only by the researchers, but also
by ethical committees who have a responsibility to con-
sider the ethical and scientific aspects of the submitted
studies. In this context there is a discrepancy between the
perceived importance of data monitoring boards and their
presence (65.3% of the protocols) and the lack of infor-
mation regarding their composition and their role. It is
encouraging that the timing of interim analysis was usu-
ally related to the number of events and almost half of the
trials adopted no more than one planned interim analysis,
thus reducing the risk of biased estimation.
Interim analyses play a fundamental role in the balance
between the need of timely information regarding the
treatment effect and the control of false positive errors and
estimation bias. Moreover, the adoption of a statistical
approach for data monitoring, no matter of which type is
chosen, effectively protects the study from the risk of
incorrect early stopping. If no stopping rule is adopted,
the probability of early stopping with a higher estimation
is noticeably increased [5,13].
Stabilization of the estimates happens when a substantial
amount of events have occurred. The finding that estima-
tion bias tends to be reduced, as expected, when the
observed number of events is closer to the planned size, is
particularly important for cancer clinical trials for non-sta-
tistical reasons. With time to event endpoints, a potential
problem with stopping a trial early is that the early sur-
vival experience with short follow-up may not accurately
reflect the complete experience with time. A new treat-
ment may be very toxic, leading to a few early deaths, but
may also have much better long-term results than the
standard treatment. Overall, the new treatment may be
viewed as better than the standard, but an early look at the
data may suggest stopping for lack of efficacy. The oppo-Trials 2008, 9:46 http://www.trialsjournal.com/content/9/1/46
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site is also possible, since early suggestions of treatment
efficacy may decline over time.
Another factor that should be considered is the scientific
and ethical relationship that links the decision of stop-
ping a trial early with its implication for ongoing trials,
addressing the same clinical question, or when a confirm-
atory trial is planned. These issues were well quantified by
a systematic review of Montori et al.6, analysing 143 ran-
domised clinical trials (RCTs) stopped early for benefit,
and generally published in high-impact medical journals
and were industry-funded drug trials. The proportion of
all RCTs published that were stopped early for benefit
increased from 0.5% in 1990–1994 to 1.2% in 2000–
2004. On average, RCTs recruited only 63% of the
planned sample and stopped after a median of 13 months
of follow-up, 1 interim analysis, and when a median of
only 66 patients had experienced the end point driving
study termination (event). The median risk ratio among
truncated RCTs was high: 0.53 (25°–75° percentiles:
0.28–0.66). One hundred thirty-five (94%) of the 143
RCTs did not report at least 1 of the following: the
planned sample size the interim analysis after which the
trial was stopped, whether a stopping rule informed the
decision, or an adjusted analysis accounting for interim
monitoring and truncation (n = 129).
Conclusion
Our results add important information relative to the
methodological quality of clinical studies. Research con-
ducted so far took into consideration only published
report and achieved qualitatively similar findings. The
DAMOCLES working party2 addressed several different
issues, using different methodological approaches: sys-
tematic literature reviews of DSMC, small group processes
in decision-making; sample surveys of reports of RCTs,
recently completed and still ongoing RCTs and policies of
major organisations involved in RCTs; case studies of
selected DSMCs; and interviews with experienced DSMC
members. The results of these studies indicated that only
about a quarter of main RCT reports mention use of a
DSMC and wide variation exists in the structure and
organisation of DSMCs, with little guidance on how they
should operate. Our research suggests that there is an
increased proportion of studies reporting use of DSMC,
but is qualitatively in agreement with these conclusions.
The study clearly indicates that much has still to be done
in making trialists aware of the statistical analyses that
should be implemented, of the impact of results of
interim analyses on the final decision to be taken, and of
the role of DSMC. Our findings may be also be of help in
the identification of the questions to be addressed by fur-
ther research for improving organisation and conduction
of clinical trials. In this sense, the survey of Italian proto-
cols seems of particular interest. Although we are aware
that the results may be valid for the Italian research con-
text and not totally generalisable to other countries, we
think that this enquiry represents a good basis for debat-
ing the issues on how to improve monitoring of clinical
trials. It also emphasises the importance of the adoption
of national registries and encourages the replication of
this kind of research in other countries were national reg-
istries of clinical trials are available.
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